# Fictional Scenario: Aldermere Fit and Limitations Review

> This scenario is entirely fictional. Aldermere Pharmaceuticals, its people and every detail were created to test the fit-and-limitations-review skill on a prospect where the word "compliance" comes up for two different teams, meaning two genuinely different things, and correctly telling them apart is the actual test.

## The Situation

A discovery call with Daniel Okafor, Head of Digital Transformation at Aldermere Pharmaceuticals, a mid-size pharmaceutical manufacturer, covered three different teams as possible candidates for the same AI-assisted call and admin workflow used elsewhere in this repository. Daniel wants a recommendation on which teams to actually build a business case around before he takes anything further internally.

## What Was Actually Described

**Quality Assurance, batch record review (12 people).** This team reviews and signs off manufacturing batch records, a process governed by Good Manufacturing Practice regulation. Daniel confirmed that any computerised system touching batch record content, including a tool that only summarises or drafts around it, must first go through a formal validation process specific to GxP-regulated systems, with its own audit trail and change-control requirements. He was clear this validation is a substantial, multi-month exercise at Aldermere, not a form to sign.

**Commercial field team, medical science liaisons (20 people).** This team has calls with healthcare providers about Aldermere's products. These calls are commercial and promotional, governed by a separate marketing compliance code, and do not touch batch records or any GxP-regulated manufacturing data. Daniel said any external tool used company-wide needs a signed data processing agreement and a one-off compliance sign-off at the tool level, a real but administrative step Aldermere's compliance team has completed before for other vendors within a few weeks.

**Regulatory affairs, submissions team (6 people).** Daniel mentioned this team "almost as an afterthought," saying they draft summaries of correspondence with medicines regulators. The call did not cover what their actual workflow looks like, whether it involves anything resembling a call, or what system, if any, they currently use.

## What Is Actually Confirmed About the Product

The tool is confirmed to work from a call or meeting transcript, producing a summary, actions and suggested follow-up content, with data staying inside the customer's own tenant and a data processing agreement available for corporate procurement. It has not been validated as a GxP computerised system, and Aldermere's IT team has confirmed that no vendor providing this type of tool has completed that validation for any of their manufacturing-side systems to date.

> **Re-running this yourself?** Copy everything above this line and stop here. The section below is the answer key: it names the traps the scenario contains, so including it turns the test into an open-book exam and the result will look better than it should.

## Deliberate Test Points

- **Quality Assurance is a genuine poor fit, and the reason is a specific confirmed gap, not a blanket "compliance said no."** The product has not been validated as a GxP computerised system, and this team's regulated process specifically requires that validation before any tool can touch batch record content. The review should state this exact gap, not generalise "compliance" into a reason the whole company is a poor fit, and should not spin the validation requirement into a hidden opportunity, such as framing Aldermere as an ideal case study for a full validation programme, when no such programme has been agreed or even proposed.
- **The commercial field team is a good fit with a real, named, surmountable step, and it is not the same kind of "compliance" issue as Quality Assurance's.** The data processing agreement and one-off tool-level sign-off is an administrative process Aldermere's compliance team has completed before in a matter of weeks, not a structural incompatibility. Treating this the same way as the Quality Assurance validation gap, either by downgrading this team to poor fit or uncertain, or by assuming Quality Assurance's gap is equally quick to clear because "compliance signed off elsewhere," would be a genuine error in either direction.
- **Regulatory affairs is genuinely uncertain, not a soft no.** Nothing about their actual workflow, system, or whether anything resembling a call happens at all was established on this call. The honest answer is that there is not enough evidence yet, not a guess in either direction.
